QQQ1.89%

Trending

SMCI26.65%

Info

home Symbol HIMSnews

Exchange: NYSE·Updated 05:12 PM EDT

HIMSHims & Hers Health Inc

$32.64

$0.03

(0.09%)

Today

Closed $32.73

$0.09

(0.28%)

After Hours

News·HIMS Stock On A 3-Day Slide: CFO Cashes Out $229K In Shares Ahead Of FDA Peptide Meeting

EarningsAug 10

Mkt Cap$7.57B

Vol9.71M

News

all

press releases

Here's How Much You Would Have Made Owning Hims & Hers Health Stock In The Last 5 Years

Hims & Hers Health (NYSE:HIMS) has outperformed the market over the past 5 years by 20.67% on an annualized basis producing an average annual return of 31.83%. Currently, Hims & Hers Health has a marketread more...

Benzinga

More News

HIMS Stock On A 3-Day Slide: CFO Cashes Out $229K In Shares Ahead Of FDA Peptide Meeting

The next major catalyst is the FDA’s July 23-24 advisory committee meeting, where regulators will consider whether seven peptides should be added to the Section 503A Bulks List.

Stocktwits

Hims & Hers Chief Accounting Officer, Irene Becklund, Announces Departure from the Company

Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced its Chief Accounting Officer, Irene Becklund will depart the company after more than seven years, effective October 9, 2026. Becklund will then serve as an advisor to the company for several months to...

Business Wire

Hims & Hers Health, Inc. (HIMS) Outpaces Stock Market Gains: What You Should Know

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $35.15, moving +2.24% from the previous trading session.

Zacks

Hims & Hers to Announce Second Quarter 2026 Financial Results on August 10, 2026

Hims & Hers Health, Inc. (Hims & Hers, NYSE: HIMS), the leading health and wellness platform, today announced that it will report second quarter 2026 financial results after the market closes on Monday, August 10, 2026. The company will host a live conference call to discuss the results at 5:00...

Business Wire

Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now?

Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks

HIMS Stock Logs Worst Week In 2 Months — Turns To Peptides Campaign Ahead Of Key FDA Meeting

An FDA advisory committee will review seven peptides for possible inclusion on the Section 503A Bulks List on July 23-24.

Stocktwits

HIMS Stock Under Pressure: BofA Warns Wegovy Churn Could Threaten Its Big H2 EBITDA Ramp

BofA flagged churn risk once subscription pricing jumps from $39 in month one to $149 in month two.

Stocktwits

Here's Why Hims & Hers Health, Inc. (HIMS) Fell More Than Broader Market

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $36.17, moving 5.51% from the previous trading session.

Zacks

Hims & Hers Health vs. Teladoc Health: Which Healthcare Stock Is a Better Buy in 2026?

Key PointsHims & Hers Health continues to drive impressive growth through its subscription-based consumer wellness platform...